Clinical Trial Update: Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Continue to Benefit From the Treatment as Judged by the Investigator [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update describes access to single-agent panobinostat for patients already on panobinostat treatment who continue to benefit, in a Novar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Neoplasms

Drugs mentioned

• Panobinostat (Panobinostat)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Hematologic Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2019-12-06